ADB-4en-PINACA

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B US: Schedule I
Identifiers
IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide
CAS Number	2659308-44-6 Y
PubChem CID	162705324
ChemSpider	103835283
UNII	76QQ7SDU32
CompTox Dashboard (EPA)	DTXSID601038864
Chemical and physical data
Formula	C19H26N4O2
Molar mass	342.443 g·mol−1
3D model (JSmol)	Interactive image
SMILES NC(=O)[C@@H](NC(=O)c1nn(CCCC=C)c2ccccc21)C(C)(C)C
InChI InChI=1S/C19H26N4O2/c1-5-6-9-12-23-14-11-8-7-10-13(14)15(22-23)18(25)21-16(17(20)24)19(2,3)4/h5,7-8,10-11,16H,1,6,9,12H2,2-4H3,(H2,20,24)(H,21,25) Key:NXDLAZXBALPFSN-UHFFFAOYSA-N

ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products,^[1] first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.^[2][3][4][5]

Legality

In the United States, the DEA has temporarily placed ADB-4en-PINACA into Schedule I status starting on December 12, 2023, for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12, 2025.^[6]

See also

• 5F-ADB-PINACA
• ADB-BINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-HEXINACA

References